ORAMA: A study to investigate EBPG impact on renal anaemia - Design and baseline data

Journal of Nephrology

Volumn 21, Issue 4, 2008, Pages 592-602

  Locatelli, Francesco ^a   Covic, Adrian ^b   Macdougall, Iain C ^c   Wiecek, Andrzej ^d  

^a A MANZONI HOSPITAL   (Italy)

^b C I PARHON NATIONAL INSTITUTE OF ENDOCRINOLOGY   (Romania)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Chronic kidney disease; Clinical decision support system; Erythropoiesis stimulating agents; European best practice guidelines; ORAMA; Renal anaemia

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERRITIN; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; ANTIANEMIC AGENT; RECOMBINANT PROTEIN;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DIALYSIS; EUROPE; EVIDENCE BASED MEDICINE; FEMALE; FERRITIN BLOOD LEVEL; GOOD CLINICAL PRACTICE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RENAL ANEMIA; TRANSFERRIN BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; FOLLOW UP; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ANEMIA; EUROPE; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 52649122798     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Eschbach JW, Aquiling T, Haley NR, Fan MH, Blagg CR. The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol. 1992;38(Suppl 1):98-103.
2. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:121-132.
3. M6ocks J. Cardiovascular mortality in haemodialysis patients treated with epoetin beta - a retrospective study. Nephron. 2000;86:455-462.
4. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(Suppl 3):11-145.
5. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63:1908-1914.
6. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis. 1997;29:541-548.
7. Navaneethan SD, Bonifati C, Schena FP, Strippoli GF. Evidence for optimal hemoglobin targets in chronic kidney disease. J Nephrol. 2006;19:640-647.
8. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron. 1991;58:129-134.
9. Moreno F, Aracil FJ, Perez R, Valderrabano F. Controlled study on the improvement of quality of life in elderly hemodialysis patients after correcting end-stage renal disease-related anemia with erythropoietin. Am J Kidney Dis. 1996;27:548-556.
10. Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis. 1989;14:478-485.
11. Collins AJ, Roberts TL, St Peter WL, Chen SC, Ebben J, Constantini E. United States Renal Data System assessment of the impact of the National kidney Foundation-Dialysis Outcomes Quality Initiative guidelines. Am J Kidney Dis. 2002;39:784-795.
12. EBPG Working Party. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant. 1999;14(Suppl 5):1-50.
13. Friedman C, Wyatt J. Evaluation methods in medical informatics. New York: SpringerVerlag; 1997.
14. Grimshaw J, Freemantle N, Wallace S, et al. Developing and implementing clinical practice guidelines. Qual Health Care. 1995;4:55-64.
15. Hunt DL, Haynes RB, Hanna SE, Smith K. Effects of computer-based clinical decision support systems on physician performance and patient outcomes: a systematic review. JAMA. 1998;280:1339-1346.
16. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant. 2005;20(Suppl 3):3-24.
17. Locatelli F, Aljama P, Barany P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2):1-47.
18. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(Suppl 2):1-249.
19. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:94-111.
20. Valderrabano F, Horl WH, Jacobs C, et al. European best practice guidelines 1-4: evaluating anaemia and initiating treatment. Nephrol Dial Transplant. 2000;15(Suppl 4):8-14.
21. Valderrabano F, Horl WH, Macdougall IC, Rossert J, Rutkowski B, Wauters JP. PRE-dialysis survey on anaemia management. Nephrol Dial Transplant. 2003;18:89-100.
22. Arenas MD, Varez-Ude F, Torregrosa V, et al. Consequences of the implementation of K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease in a population of patients on chronic hemodialysis. J Nephrol. 2007;20:453-461.
23. Eschbach JW, Adamson JW. Anemia of end-stage renal disease (ESRD). Kidney Int. 1985;28:1-5.
24. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53-61.
25. National Kidney Foundation. NKF-K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006;47(Suppl 3):16-85.
26. National Kidney Foundation. NKF-KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis. 2007;50:471-530.
27. Wiecek A, Covic A, Locatelli F, Macdougall IC; on behalf of the ORAMA Study Group. Renal anaemia: comparing current eastern and western European management practice (ORAMA). Ren Fail. 2008;30:267-276.
28. Muirhead N, Churchill DN, Goldstein M, et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol.1992;12:303-310.
29. Gotloib L, Silverberg D, Fudin R, Shostak A. Iron deficiency is a common cause of anemia in chronic kidney disease and can often be corrected with intravenous iron. J Nephrol. 2006;19:161-167.